title: Modification of BHA forestomach carcinogenesis in rats: inhibition by diethylmaleate or indomethacin and enhancement by a retinoid.
abstract: The long-term effects of butylated hydroxyanisole (BHA), in combination with various other chemicals on the development of forestomach lesions in rats were investigated. BHA is a synthetic antioxidant, and the other agents included the glutathione-depleting agent diethylmaleate (DEM), the anti-inflammatory drugs indomethacin (IM), dexamethazone (DEX), 6-aminocaproic acetate (6-ACA) and FOY (gabexate mesilate), and the vitamin all-trans-retinol acetate (RA). Concurrent treatment with BHA (1% in diet) and DEM, IM, DEX or FOY for 52 weeks inhibited development of forestomach epithelial hyperplasia as compared to BHA alone, while simultaneous treatment with RA enhanced hyperplastic development. However, the inhibition by DEX or FOY was only partial and in the DEX case, in particular, might have been due to weight loss. Since the most effective inhibitory influence on BHA-induced forestomach lesions exerted in this 1-year experiment was by DEM, a further 2-year experiment was conducted to confirm whether DEM actually can exert inhibitory effects on BHA (2% in diet)-induced forestomach carcinogenesis. The results demonstrated that induction of forestomach hyperplasias and papillomas by BHA was significantly reduced by combination treatment with DEM. Both multiplicity and incidence of forestomach papillomas were significantly decreased, while squamous cell carcinoma development showed a tendency for decrease only.
authors.affiliation: First Department of Pathology, Nagoya City University Medical School, Japan.
authors.forename: M A
authors.initials: MA
authors.lastname: Shibata
authors.forename: M
authors.initials: M
authors.lastname: Hirose
authors.forename: A
authors.initials: A
authors.lastname: Masuda
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Mutai
authors.forename: N
authors.initials: N
authors.lastname: Ito
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002083:Butylated Hydroxyanisole / Q000633:toxicity*; D003907:Dexamethasone / Q000494:pharmacology; D004336:Drug Antagonism; D006965:Hyperplasia; D008297:Male; D008298:Maleates / Q000494:pharmacology*; D010212:Papilloma / Q000139:chemically induced / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013274:Stomach Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D008298:Maleates; D002083:Butylated Hydroxyanisole; D014212:Tretinoin; D003907:Dexamethasone; C014476:diethyl maleate